ArticleWorld journal of gastroenterology2017
Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma.
Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: Evidence from a meta-analysis.Medicine · 2020Pooled it
- A nomogram based on autoantibodies for noninvasive detection of AFP-negative hepatocellular carcinoma: a multicenter study.British journal of cancer · 2025Article
- Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer.Frontiers in immunology · 2025Article
- Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure.Gut and liver · 2023Article
- Rapid, site-specific labeling of "off-the-shelf" and native serum autoantibodies with T cell-redirecting domains.Science advances · 2022Article
- A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody-antigen system.Cancer science · 2022Article
- Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients.Biomedicines · 2022Article
- An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.Frontiers in immunology · 2022Article
- The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?International journal of biological sciences · 2022Review
- Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment.International journal of molecular sciences · 2021Review
- An Autoantigen-ome from HS-Sultan B-Lymphoblasts Offers a Molecular Map for Investigating Autoimmune Sequelae of COVID-19.bioRxiv : the preprint server for biology · 2021Article
- Autoantibody signature in hepatocellular carcinoma using seromics.Journal of hematology & oncology · 2020Article
- Article
- New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma.Frontiers in oncology · 2020Review
- BiomarkersWorld journal of clinical cases · 2019Review
- 14-3-3ζ-A Novel Immunogen Promotes Inflammatory Cytokine Production.Frontiers in immunology · 2019Article
- Validated preoperative computed tomography risk estimation for postoperative hepatocellular carcinoma recurrence.World journal of gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine the prevalence and diagnostic value of autoantibodies in α-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC).
methodsFifty-six serum samples from AFP-negative HCC cases, 86 from AFP-positive HCC cases, 168 from chronic liver disease cases, and 59 from normal human controls were included in this study. Autoantibodies to nucleophosmin (NPM)1, 14-3-3zeta and mouse double minute 2 homolog (MDM2) proteins in AFP-negative HCC serum were evaluated by enzyme-linked immunosorbent assay. Partially positive sera were further evaluated by western blotting. Immunohistochemistry was used to detect the expression of three tumor-associated antigens (TAAs) in AFP-negative HCC and normal control tissues.
resultsThe frequency of autoantibodies to the three TAAs in AFP-negative HCC sera was 21.4%, 19.6% and 19.6%, which was significantly higher than in the chronic liver disease cases and normal human controls (
conclusionAutoantibodies to NPM1, 14-3-3zeta and MDM2 may be useful biomarkers for immunodiagnosis of AFP-negative HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.